Clostridium difficile: Clinical Considerations

Reviews of Infectious Diseases

Volumn 12, Issue , 1990, Pages S243-S251

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN;

ANIMAL MODEL; ANTIBIOTIC THERAPY; BACTERIAL SPORE; BACTERIUM CARRIER; CELL CULTURE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG USE; ENDOSCOPY; EPIDEMIC; GUINEA PIG; HAMSTER; HISTORY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RELAPSE;

ANIMAL; CLOSTRIDIUM; CLOSTRIDIUM INFECTIONS; COLITIS; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; RECURRENCE;

EID: 0025093525     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/12.Supplement_2.S243     Document Type: Article

References (41)

1. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136: 701–5
2. Finney J.M.T. Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp 1893;4:53–5
3. Hummel RP, Altemeier WA, Hill EO. Iatrogenic staphylococcal enterocolitis. Ann Surg 1964;160:551–60
4. Khan MY, Hall WH. Staphylococcal enterocolitis: treatment with oral vancomycin. Ann Intern Med 1966;65:1–8
5. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974;81:429–33
6. Hamre DM, Rake G, McKee CM, MacPhillamy HB. The toxicity of penicillin as prepared for clinical use. Am J Med Sci 1943;206:642–52
7. Green RH. The association of viral activation with penicillin toxicity in guinea pigs and hamsters. Yale J Biol Med 1974;47:166–81
8. Larson HE, Parry JV, Price AB, Davies DR, Dolby J, Tyrrell D.A.J., Undescribed toxin in pseudomembranous colitis. Br Med J 1977;1:1246–8
9. Hall IC, OToole E, Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935;49:390–402
10. Hafiz S. Clostridium difficile and its toxins. PhD diss, Leeds, UK: University of Leeds, 1974
11. Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med J 1981;149:6–9
12. Dzink J, Bartlett JG. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 1980; 17:695–8
13. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:5–9
14. Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981;34:1036–43
15. Aronsson B, Mollby R, Nord C-E, Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980–1982. J Infect Dis 1985; 151:476–81
16. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531–4
17. Sullivan NM, Pellett S, Wilkins TD. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun 1982;35:1032–40
18. Fekety R, Kim K-H, Brown D. Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981;70:906–8
19. Bender BS, Bennett R, Laughon BE, Greenough WB III, Gaydos C, Sears SD, Forman MS, Bartlett JG, Is Clostridium difficile endemic in chronic care facilities? Lancet 1986;2:11–3
20. Bartlett JG, Onderdonk AB, Cisneros RL. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology 1977;73:772–6
21. Browne RA, Fekety R, Silva J, Boyd DI, Work CO, Abrams GD. The protective effect of vancomycin on clindamycin- induced colitis in hamsters. Johns Hopkins Med J 1977; 141:183–92
22. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984;6(Suppl 1):S235–41
23. Bartlett JG. Treatment of Clostridium difficile colitis [editorial]. Gastroenterology 1985;89:1192–5
24. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA, McDonald M, Labrooy J, Hecker R. Antibiotic- associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89:1038–45
25. Tfeasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz M J, Lee JT Jr. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043–6
26. Cronberg S, Castor B, Thoren A. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 1984;12:276–9
27. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs. vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986;146: 1101–4
28. Smith L.D.S., King EO. Occurrence of Clostridium difficile in infections of man. J Bacteriol 1962;84:65–7
29. Hafiz S, McEntegart MG, Morton RS, Waitkins SA. Clostridium difficile in the urogenital tract of males and females. Lancet 1975;1:420–1
30. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980;1:381–3
31. Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea. A role in inflammatory bowel disease? Lancet 1980;1:383–4
32. Bartlett JG, Laughon BE, Bayless TM. Role of microbial agents in relapses of idiopathic inflammatory bowel disease. In: Bayless TM, ed. Current management of inflammatory bowel disease. Toronto: B. C. Decker, 1990 (in press)
33. Laughon BE, Viscidi RP, Gdovin SL, Yolken RH, Bartlett JG. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984;149:781–8
34. Shahrabadi MS, Bryan LE, Gaffney D, Coderre SE, Gordon R, Pai CH. Latex agglutination test for detection of Clostridium difficile toxin in stool samples. J Clin Microbiol 1984;20:339–41
35. Lyerly DM, Wilkins TD. Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol 1986;23:622–3
36. Peterson LR, Holter JJ, Shanholtzer CJ, Garrett CR, Gerding DN. Detection of Clostridium difficile toxins A (en- terotoxin) and B (cytotoxin) in clinical specimens: evaluation of a latex agglutination test. Am J Clin Pathol 1986;86:208–11
37. Gerding DN, Olson MM, Peterson LR, Teasley DG, Gebhard RL, Schwartz ML, Lee JT Jr. Clostridium difficile- associated diarrhea and colitis in adults: a prospective case- controlled epidemiologic study. Arch Intern Med 1986; 146:95–100
38. Walters B.A.J., Roberts R, Stafford R, Seneviratne E. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983;24:206–12
39. Onderdonk AB, Cisneros RL, Bartlett JG. Clostridium difficile in gnotobiotic mice. Infect Immun 1980;28:277–82
40. Gorbach SL, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG [letter]. Lancet 1987;2:1519
41. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1982;77:220–1